Precision Medicine, Biomarkers and Companion Diagnostics

The promise of individualized therapy depends on reliable markers of disease biology and drug response. Precision Medicine, Biomarkers & Companion Diagnostics brings together discovery scientists, clinical developers, laboratorians, and regulators to translate molecular insights into decisions that benefit real patients. This session examines the end-to-end workflow: from candidate biomarker discovery and analytical validation to clinical validation, utility studies, and health-technology considerations for adoption. It explains how multi-omic signatures, imaging analytics, digital pathology, and liquid biopsy are reshaping selection, stratification, and monitoring—while also addressing pre-analytical variables, assay harmonization, and cross-platform comparability. Attendees will learn how to define fit-for-purpose performance characteristics, link thresholds to outcomes, and manage bias, drift, and lot-to-lot variability in regulated environments. For professionals exploring a Pharmaceutical Science Conference, the program highlights strategies for integrating biomarkers into adaptive trials, basket/umbrella designs, and post-approval real-world evidence frameworks. The role of companion diagnostics in co-development is discussed in depth, including clinical cut-point establishment, bridging studies, and global regulatory pathways for IVDs and laboratory-developed tests.

The session also covers data governance and interoperability—from specimen tracking and chain of custody to standardized data models that allow secure reuse across studies. Economic and access considerations are addressed through case examples where biomarker-guided therapy improved effectiveness and reduced unnecessary exposure, supporting payer acceptance and equitable deployment. Whether your work focuses on assay development, clinical design, or regulatory approval, this track clarifies how to convert signals into decisions with robust evidence and transparent reporting.